T.A.C-THE-AYURVEDA-CO.
17.3.2023 10:28:38 CET | Business Wire | Press release
T.A.C - The Ayurveda Co., India's first and fastest-growing D2C omnichannel Ayurvedic lifestyle brand, has raised USD 12.2 Mn in its Series A funding round from India's largest consumer VC fund, Sixth Sense Ventures. It also saw participation from actress Kajal Agarwal, notable start-up founders and venture debt funds. It was also seen on ‘Shark Tank India’ special episode number 51.
The brand has shown unprecedented growth over the past 10 months, growing over 300%, with a strong omni-channel distributor across retail touchpoints and online channels. T.A.C has recently forayed into global markets, starting with MEA region with its Dubai launch.
Within a short span from inception T.A.C has acquired more than 2 million consumers with its bestselling Kumkumadi, Eladi & Methi ranges, and managed to raise funds even during the global funding winter. The funds will also be used for ‘digitalization of Ayurveda’ with soon to launch ‘T.A.C App’ - a revolutionary mobile-based application where users can get consultation about ayurvedic healthcare across the globe.
Shreedha Singh, Co-founder & CEO T.A.C. and Khadi Essentials added, “We will use this to replicate the love we have amassed from our millions of consumers in India to other regions. Our Kumkumadi face care range for radiance & youthful skin is most loved and our formulations are Ayurvedic with global certifications & and clinically proven results.”
Param Bhargava, Founder, T.A.C. and Khadi Essentials said, “I am excited to see the tremendous growth potential in the Ayurvedic Beauty and Personal Care (BPC) category worldwide, which is expected to grow from $12bn to $30bn in the next five years. We will be happy to partner with right stakeholders who can disrupt & exponentially grow Ayurveda & T.A.C across regions.”
Nikhil Vora, Founder & CEO Sixth Sense Ventures said, “T.A.C is garnering shelf space in areas dominated by incumbents to become an omnichannel global Beauty & Wellness brand. Thrilled to partner with the super passionate and determined duo, Param and Shreedha, to realise their vision!”
T.A.C's vision is to HEAL, which stands for Help Embrace an Ayurvedic Life. Recognizing the life-changing potential of Ayurveda, the brand offers uncompromised, pure and top-notch quality.
Choose Ayurveda, Choose T.A.C
Website - https://theayurvedaco.com/
Instagram - https://www.instagram.com/theayurvedaco/
LinkedIn - https://www.linkedin.com/company/the-ayurveda-company
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005347/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom